Prelude Capital Management’s Kite Pharma, Inc. KITE Stock Holding History

Prelude Capital Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-44,779	Closed	-$8.05M	–	1964
2017 Q3	$8.05M	Buy	44,779 +33,965	+314%	+$4.73M	0.73%	21
2017 Q2	$1.12M	Hold	10,814	–	–	0.11%	198
2017 Q1	$849K	Buy	10,814 +146	+1%	+$9.03K	0.08%	258
2016 Q4	$478K	Buy	10,668 +4,197	+65%	+$206K	0.06%	323
2016 Q3	$361K	Buy	+6,471	New	+$361K	0.04%	377

Prelude Capital Management's KITE Position: Q4 2017 in Review

Prelude Capital Management sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 44,779 shares — an estimated $8.05M sold.

Prelude Capital Management first reported a position in KITE in Q3 2016 and held it in 5 quarters. The position peaked at $8.05M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

Prelude Capital Management reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 44,779 Kite Pharma, Inc. shares in Q4 2017, an estimated $8.05M.
Prelude Capital Management first reported a position in Kite Pharma, Inc. in Q3 2016 and held it in 5 quarters.
Prelude Capital Management's Kite Pharma, Inc. position peaked at $8.05M in Q3 2017.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.